These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36968228)

  • 1. Incorporating RNA-based Risk Scores for Genomic Instability to Predict Breast Cancer Recurrence and Immunogenicity in a Diverse Population.
    Hamilton AM; Van Alsten SC; Gao X; Nsonwu-Farley J; Calhoun BC; Love MI; Troester MA; Hoadley KA
    Cancer Res Commun; 2023 Jan; 3(1):12-20. PubMed ID: 36968228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer.
    Walens A; Van Alsten SC; Olsson LT; Smith MA; Lockhart A; Gao X; Hamilton AM; Kirk EL; Love MI; Gupta GP; Perou CM; Vaziri C; Hoadley KA; Troester MA
    Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2136-2147. PubMed ID: 36129803
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Shi Z; Shen J; Qiu J; Zhao Q; Hua K; Wang H
    Theranostics; 2021; 11(15):7175-7187. PubMed ID: 34158843
    [No Abstract]   [Full Text] [Related]  

  • 4. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.
    Yang C; Zhang Z; Tang X; Zhang X; Chen Y; Hu T; Zhang H; Guan M; Zhang X; Wu Z
    Hum Cell; 2022 Jan; 35(1):199-213. PubMed ID: 34628623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer Patients.
    Hamilton AM; Hurson AN; Olsson LT; Walens A; Nsonwu-Farley J; Kirk EL; Abdou Y; Downs-Canner SM; Serody JS; Perou CM; Calhoun BC; Troester MA; Hoadley KA
    Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1341-1350. PubMed ID: 35437570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.
    Kraya AA; Maxwell KN; Wubbenhorst B; Wenz BM; Pluta J; Rech AJ; Dorfman LM; Lunceford N; Barrett A; Mitra N; Morrissette JJD; Feldman M; Nayak A; Domchek SM; Vonderheide RH; Nathanson KL
    Clin Cancer Res; 2019 Jul; 25(14):4363-4374. PubMed ID: 30914433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
    Wen WX; Leong CO
    PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study.
    Jinna ND; Van Alsten S; Rida P; Seewaldt VL; Troester MA
    Breast Cancer Res Treat; 2023 Sep; 201(2):171-181. PubMed ID: 37438515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 17-marker panel for global genomic instability in breast cancer.
    Biermann J; Nemes S; Parris TZ; Engqvist H; Werner Rönnerman E; Kovács A; Karlsson P; Helou K
    Genomics; 2020 Mar; 112(2):1151-1161. PubMed ID: 31260745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
    Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
    J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
    Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
    Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
    Liu D
    Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
    Ballot E; Galland L; Mananet H; Boidot R; Arnould L; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Bergeron A; Derangère V; Ghiringhelli F; Truntzer C; Ladoire S
    Breast Cancer Res; 2022 Nov; 24(1):80. PubMed ID: 36401316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.
    Lalonde E; Ishkanian AS; Sykes J; Fraser M; Ross-Adams H; Erho N; Dunning MJ; Halim S; Lamb AD; Moon NC; Zafarana G; Warren AY; Meng X; Thoms J; Grzadkowski MR; Berlin A; Have CL; Ramnarine VR; Yao CQ; Malloff CA; Lam LL; Xie H; Harding NJ; Mak DYF; Chu KC; Chong LC; Sendorek DH; P'ng C; Collins CC; Squire JA; Jurisica I; Cooper C; Eeles R; Pintilie M; Dal Pra A; Davicioni E; Lam WL; Milosevic M; Neal DE; van der Kwast T; Boutros PC; Bristow RG
    Lancet Oncol; 2014 Dec; 15(13):1521-1532. PubMed ID: 25456371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
    Liu D; Zhou K
    Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes.
    Ansari-Pour N; Zheng Y; Yoshimatsu TF; Sanni A; Ajani M; Reynier JB; Tapinos A; Pitt JJ; Dentro S; Woodard A; Rajagopal PS; Fitzgerald D; Gruber AJ; Odetunde A; Popoola A; Falusi AG; Babalola CP; Ogundiran T; Ibrahim N; Barretina J; Van Loo P; Chen M; White KP; Ojengbede O; Obafunwa J; Huo D; Wedge DC; Olopade OI
    Nat Commun; 2021 Nov; 12(1):6946. PubMed ID: 34836952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.